Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price objective on Trevena from $9.00 to $5.00 and set a buy rating on the stock in a research report on Thursday, May 16th.

Trevena Price Performance

NASDAQ:TRVN opened at $0.22 on Tuesday. The company has a debt-to-equity ratio of 8.35, a quick ratio of 3.60 and a current ratio of 3.60. The firm has a market cap of $4.00 million, a P/E ratio of -0.08 and a beta of 1.07. Trevena has a fifty-two week low of $0.19 and a fifty-two week high of $1.12. The firm has a 50-day simple moving average of $0.38 and a two-hundred day simple moving average of $0.51.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. The firm had revenue of $0.02 million for the quarter. Analysts predict that Trevena will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC bought a new stake in Trevena, Inc. (NASDAQ:TRVN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.